# A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

> **NCT00458159** · PHASE1 · TERMINATED · sponsor: **Celgene** · enrollment: 34 (actual)

## Conditions studied

- Myelodysplastic Syndrome

## Interventions

- **DRUG:** CC-11006

## Key facts

- **NCT ID:** NCT00458159
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05-01
- **Primary completion:** 2008-10-01
- **Final completion:** 2008-12-01
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** The compound has a benign safety profile with short-term use, clinically sig efficacy responses have not been demonstrated, or if so, have not been sustained.
- **Last updated:** 2019-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458159, "A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00458159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*